Photodynamic therapy using talaporfin sodium for non-totally resectable malignant glioma. (2023)

Peer-Reviewed Study · Fukami S; Akimoto J; Nagai K; Saito Y; Kohno M · October 28, 2023

Fukami S et al., 2023-10-28: Japanese clinical series of 18 malignant glioma patients treated with intraoperative talaporfin sodium PDT: median progression-free survival about 10.5 months and overall survival about 16.9 months in newly diagnosed glioblastoma – the current clinical brain PDT record uses talaporfin, not methylene blue.

In the 14 patients with newly diagnosed glioblastoma, the median progression-free survival was almost 10.5 months, and the median overall survival was almost 16.9 months.

Fukami S et al., 2023-10-28: Japanese clinical series of 18 malignant glioma patients treated with intraoperative talaporfin sodium PDT: median progression-free survival about 10.5 months and overall survival about 16.9 months in newly diagnosed glioblastoma – the current clinical brain PDT record uses talaporfin, not methylene blue. C8 Fukami 2024. Study type: single-arm clinical series, N=18 (15 glioblastoma, 3 anaplastic oligodendroglioma). Country: Japan (Tokyo Women's Medical University). Agent: talaporfin sodium (Laserphyrin), intraoperative PDT of the resection cavity, with radiotherapy plus temozolomide afterwards. Funder: not stated in the record. Conflicts: 'The authors declare that they have no conflicts of interest in association with this study.' Comparator: none (uncontrolled). Study type: uncontrolled series.